AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

AbbVie’s psoriasis drug risankizumab has posted strong results in its latest phase 3 trial, as the company prepares to file the drug with global regulators. An interleukin-23 inhibitor ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Geoffrey Rutledge, MD, PhD, of HealthTap, envisions a future where all patients have a virtual care doctor as their first point of contact with the health care system.